University of the Witwatersrand and CarboHyde Zrt Announce Strategic Collaboration to Develop Breast Cancer Therapeutic
Johannesburg, South Africa, and Budapest, Hungary – [28/08/2024] – The University of the Witwatersrand (WITS), a leading research institution in South Africa, and CarboHyde Zrt, a pharmaceutical company based in Hungary, have entered into a strategic collaboration to advance the development of a novel breast cancer therapeutic. This partnership aims to accelerate the development of this asset further while securing funding opportunities within Europe and ensuring the successful progress of this promising therapeutic from research to market.
The collaboration between WITS and CarboHyde will be executed in multiple phases: first, finishing the preclinical studies, and later, starting clinical trials together or with other partners.
This collaboration marks a significant milestone in the fight against breast cancer, combining the strengths of two innovative organizations across continents. By pooling their resources, expertise, and networks, WITS and CarboHyde aim to bring this cutting-edge therapeutic to market, benefiting patients and healthcare systems worldwide.
For more information, please contact CarboHyde at info@carbohyde.com
About the University of the Witwatersrand: The University of the Witwatersrand (WITS) is a leading research-intensive institution based in Johannesburg, South Africa. WITS is dedicated to advancing knowledge through impactful research and is recognized globally for its contributions to science and innovation.
About CarboHyde Zrt: CarboHyde is a pharmaceutical company based in Budapest, Hungary, specializing in carbohydrate chemistry, including cyclodextrins. CarboHyde focuses on creating innovative solutions and collaborating with partners worldwide to bring breakthrough technologies to market in the pharmaceutical arena.